Send to

Choose Destination
Immunotherapy. 2019 Jan;11(1):37-44. doi: 10.2217/imt-2018-0089.

Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.

Author information

Department of Hematology, Xinqiao Hospital, Army Medical University, Chongqing, People's Republic of China.
Division of Periodontology, Diagnostic Sciences & Dental Hygiene, & Division of Biomedical Sciences, Herman Ostrow School of Dentistry, University of Southern California, Los Angeles, CA, USA.


The chimeric antigen receptor T (CAR-T) cells play an antileukemia role, and can be used to treat or prevent relapse by targeting minimal residual disease for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, the infusion of allogeneic CAR-T cells may also cause graft-versus-host disease, which limited their applications during and after allo-HSCT. In this review, we discuss the clinical trials that applying CAR-T cells before allo-HSCT and the use of donor-derived CAR-T cells as conditioning regimen during allo-HSCT. At last, we analyzed the effect of donor-derived CAR-T cells on preventive infusion after allo-HSCT.


CAR-T cells; acute lymphoblastic leukemia; acute myeloid leukemia; allogeneic CAR-T cells; allogeneic hematopoietic stem cell transplantation; conditioning regimen; donor-derived CAR-T cells; hematological malignancies; preventive infusion

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center